No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
ABT241227P116000
- 2.36
- +0.39+19.80%
15min DelayClose Dec 23 16:00 ET
2.73High2.36Low
2.73Open1.97Pre Close2 Volume509 Open Interest116.00Strike Price509.00Turnover14.85%IV0.59%PremiumDec 27, 2024Expiry Date1.69Intrinsic Value100Multiplier4DDays to Expiry0.67Extrinsic Value100Contract SizeAmericanOptions Type-0.8269Delta0.1549Gamma62.98Leverage Ratio-0.0484Theta-0.0074Rho-52.08Eff Leverage0.0300Vega
Intraday
- 5D
- Daily
News
DexCom, Abbott Agree to Settlement in Patent Litigation
Express News | Abbott: Agreement Will Result in Dismissal of All Pending Cases in Courts, Patent Offices Worldwide - Website
Express News | Abbott: There Are No Financial Payments Associated With Settlement From Either Abbott or Dexcom
Express News | Abbott: Agrees to Global Continuous Glucose Monitoring Litigation Settlement With Dexcom
Abbott Laboratories' (NYSE:ABT) Investors Will Be Pleased With Their Respectable 43% Return Over the Last Five Years
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $135